Clinical Trial Update: Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating resiniferatoxin for intractable cancer pain was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer Pain

Drugs mentioned

• Resiniferatoxin (resiniferatoxin)

Snippet

Sponsor: Sorrento Therapeutics, Inc. | Conditions: Pain, Intractable, Pain Cancer | Phase 3 | Status: WITHDRAWN